Telix Pharmaceuticals (TLX) Investor Day 2025 summary

Strategic Vision and Business Model

• Built an integrated radiopharmaceutical ecosystem with a specialist commercial organization and deep pipeline, focusing on urologic oncology and expanding into other disease areas.

• Emphasizes a theranostic strategy, developing both imaging and therapeutic agents for each target, enabling self-financed growth and de-risked clinical trials.

• International expansion underway, with new manufacturing capabilities in Europe and Japan, and a two-track U.S. distribution approach combining partners and in-house infrastructure.

• Revenue diversification and reinvestment into therapy programs, with over 60% of R&D now focused on therapeutics.

• Recent acquisitions (e.g., RLS, ARTMS, Imaginab) and investments in manufacturing and supply chain strengthen global scale and reliability.

Precision Medicine, Commercial Growth, and Financial Performance

• Achieved 62% year-over-year growth, driven by Illuccix and the launch of Gozellix, with ongoing global rollout and label expansions.

• Q1 2025 revenue reached $151M from Illuccix sales, up 35% YoY, with $33M from RLS Radiopharmacies.

• U.S. PSMA imaging market opportunity projected to grow from $2.5B+ to $6.7B with new indications and label expansions.

• Gozellix enhances reach to underserved rural markets, leveraging 266 manufacturing and distribution points.

• Revenue and earnings growth expected through product and geographic expansion, with a focus on sustainable profit from 2028 onward.

Therapeutics Pipeline and Clinical Development

• Late-stage assets include TLX591 (prostate, phase 3), TLX250 (renal cell carcinoma), and TLX101 (glioblastoma), with multiple next-generation alpha programs in development.

• TLX591 antibody offers improved tumor retention, reduced off-target toxicity, and simplified dosing.

• TLX250 shows promising disease control in advanced renal cell carcinoma, with pivotal monotherapy and combination trials underway.

• TLX101 (I-131) for glioblastoma demonstrates encouraging survival in early studies; pivotal IPACS Bright trial to open in H2 2024.

• Advancing next-gen alpha therapies (TLX592, TLX252) and pan-cancer FAP-targeting agent (TLX400) into clinical development.